| scholarly article | Q13442814 |
| P50 | author | Amit Choudhary | Q90350755 |
| Kurt J Cox | Q91034455 | ||
| P2093 | author name string | Donghyun Lim | |
| Basudeb Maji | |||
| Qingxuan Zhou | |||
| Debasish Manna | |||
| Soumyashree A Gangopadhyay | |||
| P2860 | cites work | Concerning RNA-guided gene drives for the alteration of wild populations | Q21128771 |
| A CRISPR-Cas9 gene drive system targeting female reproduction in the malaria mosquito vector Anopheles gambiae | Q24456430 | ||
| Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito Anopheles stephensi | Q24456431 | ||
| Rapid and orthogonal logic gating with a gibberellin-induced dimerization system | Q24609546 | ||
| CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes | Q24625361 | ||
| Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation | Q26775746 | ||
| Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference | Q26852489 | ||
| Repair of strand breaks by homologous recombination | Q27012688 | ||
| Manipulating signaling at will: chemically-inducible dimerization (CID) techniques resolve problems in cell biology | Q27024489 | ||
| Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA | Q27681727 | ||
| CRISPR-Cas: biology, mechanisms and relevance | Q28069426 | ||
| Therapeutic genome editing: prospects and challenges | Q28087380 | ||
| Genome editing. The new frontier of genome engineering with CRISPR-Cas9 | Q28252298 | ||
| Chemically controlled protein assembly: techniques and applications | Q28278197 | ||
| RNA-guided gene activation by CRISPR-Cas9-based transcription factors | Q28295458 | ||
| Harnessing CRISPR-Cas9 immunity for genetic engineering | Q29114115 | ||
| One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering | Q29547524 | ||
| Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system | Q29615782 | ||
| CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering | Q29615783 | ||
| DNA targeting specificity of RNA-guided Cas9 nucleases | Q29615793 | ||
| High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells | Q29616045 | ||
| Evolution and classification of the CRISPR-Cas systems | Q29616645 | ||
| CRISPR RNA-guided activation of endogenous human genes | Q29617072 | ||
| An updated evolutionary classification of CRISPR-Cas systems | Q33660852 | ||
| Complex transcriptional modulation with orthogonal and inducible dCas9 regulators. | Q33704483 | ||
| Genetic and epigenetic control of gene expression by CRISPR-Cas systems | Q33777855 | ||
| Aptazyme-embedded guide RNAs enable ligand-responsive genome editing and transcriptional activation | Q33861368 | ||
| Disabling Cas9 by an anti-CRISPR DNA mimic | Q33898855 | ||
| Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein | Q33900031 | ||
| DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. | Q33931841 | ||
| Bacteriophage genes that inactivate the CRISPR/Cas bacterial immune system. | Q34034778 | ||
| Nuclease-Mediated Gene Therapies for Inherited Metabolic Diseases of the Liver. | Q52429666 | ||
| PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery. | Q52688524 | ||
| A CRISPR–Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes | Q57072352 | ||
| Base editing: precision chemistry on the genome and transcriptome of living cells | Q57464865 | ||
| Mosaicism in CRISPR/Cas9-mediated Genome editing | Q57802324 | ||
| Discovery of widespread type I and type V CRISPR-Cas inhibitors | Q59345200 | ||
| Systematic discovery of natural CRISPR-Cas12a inhibitors | Q59345201 | ||
| StaPLs: versatile genetically encoded modules for engineering drug-inducible proteins | Q59357736 | ||
| Chemogenetic control of gene expression and cell signaling with antiviral drugs | Q59357737 | ||
| Controlling CRISPR-Cas9 with ligand-activated and ligand-deactivated sgRNAs | Q64060426 | ||
| HDAd5/35 Adenovirus Vector Expressing Anti-CRISPR Peptides Decreases CRISPR/Cas9 Toxicity in Human Hematopoietic Stem Cells | Q64376811 | ||
| p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells | Q64389467 | ||
| CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response | Q89070233 | ||
| CRISPR-Cas13 Precision Transcriptome Engineering in Cancer | Q90320311 | ||
| Small-molecule displacement of a cryptic degron causes conditional protein degradation | Q39513760 | ||
| An auxin-based degron system for the rapid depletion of proteins in nonplant cells. | Q39774277 | ||
| A Broad-Spectrum Inhibitor of CRISPR-Cas9. | Q40068953 | ||
| Targeted DNA methylation in human cells using engineered dCas9-methyltransferases. | Q40104894 | ||
| Inhibition Mechanism of an Anti-CRISPR Suppressor AcrIIA4 Targeting SpyCas9. | Q40164344 | ||
| A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo | Q40236381 | ||
| Inhibition of CRISPR-Cas9 with Bacteriophage Proteins | Q40389062 | ||
| Rapidly inducible Cas9 and DSB-ddPCR to probe editing kinetics. | Q40489156 | ||
| Writing of H3K4Me3 overcomes epigenetic silencing in a sustained but context-dependent manner | Q41732083 | ||
| General method for regulating protein stability with light | Q41900311 | ||
| The Anti-CRISPR Story: A Battle for Survival. | Q41922793 | ||
| Locus-specific histone deacetylation using a synthetic CRISPR-Cas9-based HDAC | Q41950227 | ||
| Genome Editing: Insights from Chemical Biology to Support Safe and Transformative Therapeutic Applications | Q45069586 | ||
| Anti-CRISPRdb: a comprehensive online resource for anti-CRISPR proteins | Q45873209 | ||
| A Single-Chain Photoswitchable CRISPR-Cas9 Architecture for Light-Inducible Gene Editing and Transcription. | Q45981156 | ||
| Editing the Genome Without Double-Stranded DNA Breaks. | Q45996655 | ||
| Drug-tunable multidimensional synthetic gene control using inducible degron-tagged dCas9 effectors | Q46293323 | ||
| Inactivation of CRISPR-Cas systems by anti-CRISPR proteins in diverse bacterial species. | Q46495756 | ||
| Repair of a Site-Specific DNA Cleavage: Old-School Lessons for Cas9-Mediated Gene Editing | Q47230819 | ||
| Protein inhibitors of CRISPR-Cas9. | Q47282137 | ||
| Conditional Degrons for Controlling Protein Expression at the Protein Level | Q47310894 | ||
| RNA editing with CRISPR-Cas13. | Q47410076 | ||
| Anti-CRISPR: discovery, mechanism and function. | Q47603251 | ||
| Multidimensional Control of Cas9 by Evolved RNA Polymerase-Based Biosensors. | Q47951224 | ||
| Orthogonal Genetic Regulation in Human Cells Using Chemically Induced CRISPR/Cas9 Activators | Q48092539 | ||
| Can CRISPR-based gene drive be confined in the wild? A question for molecular and population biology. | Q48164968 | ||
| Emerging Approaches for Spatiotemporal Control of Targeted Genome with Inducible CRISPR-Cas9. | Q48262196 | ||
| Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. | Q49959418 | ||
| Gene Drive: Evolved and Synthetic | Q50315120 | ||
| The Biology of CRISPR-Cas: Backward and Forward. | Q51148515 | ||
| The dTAG system for immediate and target-specific protein degradation. | Q52340959 | ||
| Field-deployable viral diagnostics using CRISPR-Cas13. | Q52421894 | ||
| Efficient isolation of specific genomic regions and identification of associated proteins by engineered DNA-binding molecule-mediated chromatin immunoprecipitation (enChIP) using CRISPR. | Q34037845 | ||
| Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex | Q34042665 | ||
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. | Q34043681 | ||
| Genome editing. The mutagenic chain reaction: a method for converting heterozygous to homozygous mutations | Q34043840 | ||
| Multiple mechanisms for CRISPR-Cas inhibition by anti-CRISPR proteins | Q34045038 | ||
| Cheating evolution: engineering gene drives to manipulate the fate of wild populations | Q34046168 | ||
| A CRISPR-based approach for targeted DNA demethylation | Q34047222 | ||
| Targeted DNA demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic domain fusions | Q34047321 | ||
| Multidimensional chemical control of CRISPR-Cas9. | Q34047628 | ||
| Recognizing and exploiting differences between RNAi and small-molecule inhibitors | Q34074675 | ||
| Method for targeting protein destruction by using a ubiquitin-independent, proteasome-mediated degradation pathway | Q34085131 | ||
| Regulation of cellular polyamines by antizyme | Q34193267 | ||
| Somatic mosaicism and allele complexity induced by CRISPR/Cas9 RNA injections in mouse zygotes | Q34200242 | ||
| An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells | Q34424914 | ||
| Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation | Q34443093 | ||
| GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases | Q34454104 | ||
| CRISPR-Cas9-based photoactivatable transcription system. | Q34459593 | ||
| A split-Cas9 architecture for inducible genome editing and transcription modulation | Q34460920 | ||
| A light-inducible CRISPR-Cas9 system for control of endogenous gene activation | Q34461908 | ||
| Inducible in vivo genome editing with CRISPR-Cas9 | Q34463380 | ||
| Small molecule-triggered Cas9 protein with improved genome-editing specificity | Q34470608 | ||
| Optical Control of CRISPR/Cas9 Gene Editing. | Q34473380 | ||
| Photoactivatable CRISPR-Cas9 for optogenetic genome editing | Q34480785 | ||
| CRISPR transcriptional repression devices and layered circuits in mammalian cells | Q34495607 | ||
| Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch | Q34524602 | ||
| Reprogrammable CRISPR/Cas9-based system for inducing site-specific DNA methylation. | Q34526213 | ||
| Development of Light-Activated CRISPR Using Guide RNAs with Photocleavable Protectors | Q34538256 | ||
| Directing cellular information flow via CRISPR signal conductors | Q34539432 | ||
| A chemical-inducible CRISPR-Cas9 system for rapid control of genome editing. | Q34540074 | ||
| Induced protein degradation: an emerging drug discovery paradigm | Q34545841 | ||
| Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection | Q34770058 | ||
| Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds | Q34979506 | ||
| Engineering the ABA plant stress pathway for regulation of induced proximity | Q35031343 | ||
| Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. | Q35060760 | ||
| Multicolor CRISPR labeling of chromosomal loci in human cells. | Q35190002 | ||
| Chemical biology strategies for posttranslational control of protein function | Q35264368 | ||
| Highly efficient Cas9-mediated transcriptional programming | Q35372727 | ||
| Determining the specificities of TALENs, Cas9, and other genome-editing enzymes | Q35422003 | ||
| Functional annotation of native enhancers with a Cas9-histone demethylase fusion. | Q35554363 | ||
| High-throughput functional genomics using CRISPR-Cas9. | Q35597703 | ||
| A complex task? Direct modulation of transcription factors with small molecules | Q35642431 | ||
| Tunable and reversible drug control of protein production via a self-excising degron. | Q35977821 | ||
| Creating small-molecule-dependent switches to modulate biological functions | Q36056255 | ||
| The therapeutic application of CRISPR/Cas9 technologies for HIV. | Q36089328 | ||
| Use of herpes virus amplicon vectors to study brain disorders | Q36277709 | ||
| Conditional control of protein function | Q36373804 | ||
| Repurposing the CRISPR-Cas9 system for targeted DNA methylation | Q37076267 | ||
| High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity | Q37196274 | ||
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system | Q37214501 | ||
| Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing | Q37289829 | ||
| A computationally engineered RAS rheostat reveals RAS-ERK signaling dynamics | Q37510558 | ||
| Promoting Cas9 degradation reduces mosaic mutations in non-human primate embryos | Q37622753 | ||
| Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization | Q37661378 | ||
| Chemical inducers of targeted protein degradation | Q37690526 | ||
| To acquire or resist: the complex biological effects of CRISPR-Cas systems | Q38192284 | ||
| The dawn of active genetics. | Q38667483 | ||
| Naturally Occurring Off-Switches for CRISPR-Cas9. | Q38725824 | ||
| Editing DNA Methylation in the Mammalian Genome | Q38744151 | ||
| Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. | Q38801430 | ||
| Structural basis of CRISPR-SpyCas9 inhibition by an anti-CRISPR protein | Q38817347 | ||
| CRISPR/Cas9 in Genome Editing and Beyond | Q38825624 | ||
| An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo | Q38904501 | ||
| Targeted protein degradation by PROTACs | Q38949410 | ||
| Targeted Protein Degradation by Small Molecules | Q38978952 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Cas9 | Q16965677 |
| CRISPR | Q412563 | ||
| CRISPR-Cas method | Q17310682 | ||
| P304 | page(s) | 234-244 | |
| P577 | publication date | 2019-01-22 | |
| P1433 | published in | Biochemistry | Q764876 |
| P1476 | title | Precision Control of CRISPR-Cas9 Using Small Molecules and Light | |
| P478 | volume | 58 |
| Q89765378 | Allosteric regulation of CRISPR-Cas9 for DNA-targeting and cleavage |
| Q92654317 | Applying switchable Cas9 variants to in vivo gene editing for therapeutic applications |
| Q64882188 | CRISPR-Cas-Mediated Chemical Control of Transcriptional Dynamics in Yeast. |
| Q89477616 | CRISPR-Cas9 Genome Editing in Human Cell Lines with Donor Vector Made by Gibson Assembly |
| Q100490707 | CRISPRoff enables spatio-temporal control of CRISPR editing |
| Q104510319 | Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics |
| Q98463447 | Engineering designer beta cells with a CRISPR-Cas9 conjugation platform |
| Q100455120 | Modulating gene regulation to treat genetic disorders |
| Q90237942 | Spatiotemporal Control of CRISPR/Cas9 Function in Cells and Zebrafish using Light-Activated Guide RNA |
Search more.